Morris, Manning & Martin advised Biofrontera AG in its strategic restructuring agreement with Biofrontera Inc.
Biofrontera AG, a German biopharmaceutical company specializing in the development and commercialization of prescription dermatological products, has closed its agreement with Biofrontera Inc. to transfer all U.S. commercial, regulatory, manufacturing, and intellectual property assets related to Ameluz® and RhodoLED®.
The agreement allows Biofrontera AG to share in the future success of the U.S. business through ongoing earnout payments and a 10% ownership stake in Biofrontera Inc., and also provides for Biofrontera Inc.’s assumption of certain litigation obligations and expenses of Biofrontera AG, while Biofrontera Inc. gains full operational control to drive market growth. The transaction underscores both companies’ commitment to advancing innovative dermatology treatments and expanding patient access in the U.S.
The MMM team was led by Partners Seth Weiner and Mark Stern, with support from Tim Dodson and Abani Rollins.
